Tislelizumab Combined With Lenvatinib for Perioperative Treatment of Resectable Primary Hepatocellular Carcinoma
This is a prospective, one-arm, phase II clinical study of Tislelizumab combined with Lenvatinib for perioperative treatment of resectable primary hepatocellular carcinoma with a high risk of recurrence.
Resectable Hepatocellular Carcinoma
DRUG: Tislelizumab combined with Lenvatinib
Safety as measured by the number of grade 3 and grade 4 adverse events that occurred when subjects participated in the study, as defined by CTCAE v5.0., 36 months|Feasibility as measured by rate of enrollment, It's defined as a delay of surgery for any reason no more than 49 days compared to the specified planned surgery time (i.e., delay of surgery â‰¤42 days and scheduled surgery for 7 days)., 3 months
objective response rate(ORR), 2 months|1-year disease-free survival rate (1-year DFS%), 12 months|pathological complete response(pCR), 3 months|2-year disease-free survival rate (2-year DFS%), 24 months|disease-free survival(DFS), 24 months|adverse reactions, AEs and SAE, 36 months
To explore genomic biomarkers of clinical remission/drug resistance (TMB, TNB, ITH, HLA subtype, HLA-LOH ) in combination with Tislelizumab and Lenvatinib., 36 months|Identification of tumor microenvironmental biomarkers (tumor Infiltrating lymphocytes, biomarkers expressed on T cells ) for clinical remission/drug resistance in combination with Tislelizumab and Lenvatinib., 36 months|To investigate the clinical efficacy of PD-L1 expression in predicting the combination of Tislelizumab and Lenvatinib., 36 months
This is a prospective, one-arm, phase II clinical study of Tislelizumab combined with Lenvatinib for perioperative treatment of resectable primary hepatocellular carcinoma with a high risk of recurrence.